TD Cowen Lowers Marvell Technology's Price Target to $60

Published 1 days agoMRVL

TD Cowen Lowers Marvell Technology's Price Target to $60

TD Cowen has recently adjusted its price target for Marvell Technology Inc. to $60, down from a previous target of $95. This change reflects shifts in the evaluation of Marvell's market performance and potential by TD Cowen's analysts.

The adjustment was made by TD Cowen's analyst, Joshua Buchalter, who pointed to a challenging market environment with limited upside potential as the primary reason for the revision. Despite the decrease, Buchalter maintains confidence in Marvell's strategic direction, supported by the company's ability to perform strongly even in a difficult sector climate, as reported by Investing.com.

Marvell Technology remains focused on exceeding its Fiscal Year 2025 AI targets, demonstrating resilience and effective execution of its plans. While the revised price target highlights immediate market concerns, TD Cowen continues to hold a positive outlook on Marvell's long-term growth, particularly as demand for 5G technology expands.

Share this article

Twitter Facebook LinkedIn

Recent Articles

No New LinkedIn Layoff Reports, Past Cuts Highlighted

No New LinkedIn Layoff Reports, Past Cuts Highlighted

13 minutes agoMSFT

As of June 2, 2025, there have been no recent reports confirming that LinkedIn has planned to cut 281 jobs in California. The most significant recent layoffs at the company were announced in October 2023, when LinkedIn revealed it would reduce approximately 668 positions across its engineering, product, talent, and finance departments. Earlier, in May 2023, LinkedIn had also announced a decision to cut 716 jobs and shut down its job application platform in mainland China. This move was driven by changes in customer behavior and slower revenue growth, as noted by KDRV News. Considering the absence of new reports regarding the alleged 281 job cuts, it appears this information may pertain to outdated events or another organization. LinkedIn's recent layoff strategies reflect adjustments to market shifts rather than emerging policy changes.

TSMC Eyes UAE for Semiconductor Plant Amid U.S. Concerns

TSMC Eyes UAE for Semiconductor Plant Amid U.S. Concerns

28 minutes agoTSM

Taiwan Semiconductor Manufacturing Co. (TSMC) is reportedly exploring the possibility of establishing a semiconductor manufacturing facility in the United Arab Emirates. This news comes as the UAE is considering financing substantial semiconductor projects with potential collaborations involving TSMC and Samsung Electronics, according to Reuters. However, U.S. officials have raised concerns about advanced AI chip technologies potentially making their way to China through the UAE. Talks are underway that involve the provision of U.S. oversight on chip production and shipments from any prospective factories in the UAE, highlighting the geopolitical complexities of the situation, as reported by The Decoder. For now, TSMC has indicated that it remains focused on its current international projects and does not have any new investment plans to reveal, as noted by the Taipei Times. This development underscores the delicate balance between global technological expansion and international security concerns in the semiconductor sector.

Meta Enhances Advertising with Advanced AI Tools

Meta Enhances Advertising with Advanced AI Tools

43 minutes agoMETA

Meta Platforms is making significant strides in automating its advertising processes by integrating advanced artificial intelligence (AI) technologies. One of its pivotal advancements, the Advantage+ Shopping Campaigns, introduced in August 2022, employs AI to streamline ad creation by automating up to 150 creative combinations. Following this, the AI Sandbox launched in May 2023, allowing advertisers to experiment with generative AI features like text variation and image creation to optimize their ads. Most notably, Meta has continued to expand its suite of AI-powered advertising tools, unveiling new features in November 2023 that enhance lead generation and automate targeting, creative aspects, placements, and budgeting optimizations. In December 2024, Meta announced the introduction of Andromeda, a sophisticated machine learning system aimed at improving the efficiency of ad recommendations. This development signifies a leap forward in AI-driven ad personalization. Earlier that year, in May, Meta also rolled out generative AI-powered ad creativity tools designed to help advertisers automate the creation of engaging ad content, including varied images and text. These innovations underscore Meta's strategy to leverage AI in automating ad creation, boosting efficiency, and enhancing campaign performance. This initiative aligns with the company's broader goal of utilizing AI to improve its advertising operations, as noted by a report from Reuters. The ongoing development and implementation of these AI tools demonstrate Meta's commitment to maintaining a competitive edge in the digital advertising landscape.

FDA Approves Moderna's Latest COVID Vaccine for Older Adults and High-Risk Groups

FDA Approves Moderna's Latest COVID Vaccine for Older Adults and High-Risk Groups

58 minutes agoMRNA

The U.S. Food and Drug Administration has given the green light to Moderna's new COVID-19 vaccine, mNEXSPIKE, which is specifically aimed at adults aged 65 and older, as well as individuals between 12 and 64 years old who have at least one underlying health condition. This important development seeks to provide enhanced protection for those most vulnerable to severe impacts of the virus. As reported by Reuters, this latest approval aligns with the FDA's guidelines for dealing with populations particularly at risk. Moderna's mNEXSPIKE vaccine stands out for its lower dosage, approximately one-fifth of the original Spikevax formulation, due to advances in its immune-targeting mechanisms. This revised vaccine design is not only more efficient but also better suited for refrigerator storage, making it easier to distribute and increasing its shelf life. The approval comes on the heels of revealing clinical trial results that showed the vaccine's performance as at least on par with its predecessor, with a noted 13.5% higher efficacy in older adults. Amid a backdrop of decreasing demand for earlier vaccines, the FDA's approval sets the stage for mNEXSPIKE's anticipated release, targeting the 2025-2026 respiratory virus season. Meanwhile, Moderna has paused its flu-COVID combination vaccine application in order to gather additional efficacy data. This cautious approach reflects the company's strategy of ensuring safety and effectiveness in their vaccination offerings, as noted by Axios. Such strategic decisions continue to shape Moderna's response to an evolving health landscape.